Shanghai RAAS initiates share repurchase program

Shanghai RAAS Blood Products (SZSE:002252) announced the commencement of its previously approved share repurchase program, aimed at implementing employee stock ownership or equity incentive plans. On April 2, 2025, the company executed its first repurchase, acquiring 8,299,910 company shares via a dedicated securities account through centralized bidding. This represents approximately 0.13% of the company's total share capital. The highest transaction price was CNY 7.09 per share, while the lowest was CNY 7.02 per share, resulting in a total transaction value of CNY 58,555,083.60, excluding transaction related expenses. The company confirms this repurchase aligns with the parameters of the approved plan and relevant regulations, with further buybacks planned depending on market conditions.